share_log

Qualigen Therapeutics Partners With TD2 For Phase 1 Clinical Development Of QN-302 For The Treatment Of Advanced Or Metastatic Solid Tumors

Benzinga ·  Aug 17, 2023 08:33

Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical development of lead drug candidate QN-302. Qualigen received US FDA IND clearance earlier this month to initiate a Phase 1 clinical trial of QN-302, a small molecule G-Quadruplex (G4)-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors.

Tariq Arshad, M.D., M.B.A., Chief Medical Officer, stated: "I am delighted...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment